Maiwald Magazine

Press Coverage

5 Dec 2025 - Press Coverage

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement.

Royalty Pharma and Denali have entered into a $275 million financing agreement which, pursuant to a synthetic royalty agreement, is based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali’s lead investigational TransportVehicle™-enabled enzyme rep...

25 Aug 2025 - Press Coverage

Royalty Pharma acquires licence interest for Amgen’s Imdelltra – Maiwald advises on transaction

Royalty Pharma has acquired a royalty interest in Amgen's Imdelltra, an innovative BiTE antibody for the treatment of small cell lung cancer, from BeOne Medicines for an upfront payment of $885 million. The agreement allows BeOne to sell additional royalty rights in Imdelltr...

14 Jul 2025 - Press Coverage

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization of Revolution’s RAS(ON) inhibitor portfolio, particularly the clinical advancement of lead candida...

Maiwald in the press

Publications

13 Dec 2025 - Publication

‘Missed opportunity’ as SPCs caught between human and veterinary medicinal products, Managing IP, 2025

The conditions for the grant of a supplementary protection certificate (SPC) have, since the SPC Regulation entered into force in 1993, been the subject of numerous national d...

10 Oct 2025 - Publication

Patentable AI applications under the EPC – from the technical perspective (English only)

Fabian Kiendl and Christian Schäflein examine how AI engineering can yield patentable inventions and consider the protection of such solutions in automotive technology under ...

2 Sep 2025 - Publication

How UPC’s first ruling on second medical use infringement reflects German practice, ManagingIP 2025

In its ruling on EP 3 536 712 B1, the Düsseldorf Local Division of the UPC for the first time outlined crucial criteria for patent infringement based on second medical use cl...

All publications

Events

Mon.

19 Jan 2026 |Upcoming

5th Pharma & Biotech Patent Litigation Conference, Amsterdam

The „Pharma & Biotech Patent Litigation Summit Europe 2026“ is a key industry meeting point for experts in pharmaceutical and biotech patent litigation in Europe. It focuses on current developments at the UPC, recent case law, SPC issues, and strategic questions around cross‑border enforcement of patents in the life sciences sector.

Tue.

10 Mar 2026 |Upcoming

2nd European Summit for Women Leaders in Life Science Law

Maiwald will once again participate in the “European Summit for Women Leaders in Life Sciences Law” in Brussels in 2026 and is looking forward to engaging with international experts from across the life sciences legal community. The conference offers practical insights into current legal and regulatory developments i...

Wed.

8 Apr 2026 |Upcoming

Maiwald at the 33rd Annual IP Conference of the Fordham IP Institute in New York

The 33rd Annual IP Law & Policy Conference of the renowned Fordham Intellectual Property Institute will take place from 8 to 10 April 2026 at Fordham Law School in New York. This event brings together leaders from government, the judiciary, academia and business worldwide to discuss current challenges in intellectual property.

Tue.

18 Nov 2025 |Past Event|Vortag Live

Joint international symposium with Oblon on November 18, 2025

The law firms Oblon and Maiwald jointly hosted an international symposium on: U.S. and European Patent Practice – Important Aspects for Practitioners We provided updates on the latest developments and current aspects of IP practice in the United Stat...

All events

News and Releases

Maiwald Blog

New fee schedule for the Unified Patent Court (UPC) from 1 January 2026

Why Patent Defense and Military Technologies?

Turn one into several – what Rule 80 EPC says about using several independent claims to defend one independent claim

Press Coverage

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement.

Royalty Pharma acquires licence interest for Amgen’s Imdelltra – Maiwald advises on transaction

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Staff News

Dr Iris Müller and Dr Gabriel Kiefl sworn in as German patent attorneys

Marvin Bäumel sworn in as German patent attorney

Maiwald appoints Alexander Feil, Dr. Johannes Scholz and Dr. Fabian Wiescher as Counsel

Publications

‘Missed opportunity’ as SPCs caught between human and veterinary medicinal products, Managing IP, 2025

Patentable AI applications under the EPC – from the technical perspective (English only)

How UPC’s first ruling on second medical use infringement reflects German practice, ManagingIP 2025

Awards

IAM Strategy 300 Global Leaders 2026

JUVE Patent Rankings Germany 2025

Managing IP’s Rising Stars 2025

Events

5th Pharma & Biotech Patent Litigation Conference, Amsterdam

2nd European Summit for Women Leaders in Life Science Law

Maiwald at the 33rd Annual IP Conference of the Fordham IP Institute in New York

Joint international symposium with Oblon on November 18, 2025